Emerging data in platinum resistance advanced ovarian cancer

Emerging data in platinum resistance advanced ovarian cancer - Webinar

Description

Tuesday, May 21, 2024
9:00 PM UTC (see all time zones)
Duration approximately 30 minutes

Led by Dr. Floor Backes and Dr. Wendel Naumann, the Advances & Updates workgroup of the IGCS Education Committee collaborates with our industry partners year-round to provide our global community with current and future therapeutics in gynecologic cancer. Thanks to the support from ImmunoGen, this webinar is complimentary for all attendees

Attended previous IGCS webinars? If you have attended IGCS webinars in the past, you may already have an IGCS account and creating a new account is not required. If unsure of your login information, you may reset your information by selecting "Forgot Password" at login or contact education@igcs.org.

Faculty Information

	Lainie P. Martin, MD Leader, Gynecology/Oncology Program of Hematology-Oncology Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania Associate Professor of Obstetrics and Gynecology University of Pennsylvania Perelman School of Medicine USA
	David O’Malley, MD Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute Professor Director, Division of Gynecologic Oncology Co-Director, Gyn Oncology Phase I Program USA

Supported in part by

Summary

Availability:

No future session

Cost:

FREE

Create Account

Recommended

Newly Opened Phase 3 Study for Low Grade Serous Ovarian Cancer

The RAMP 301 trial is evaluating the novel combination of avutometinib + defactinib versus investigator’s choice of therapy in patients with recurrent low grade serous ovarian cancer.

Free

Personalized Management of Advanced or Recurrent Endometrial Cancers: Navigating pMMR, dMMR Subtypes, or Molecular Classifications

This course offers an in-depth exploration of personalized treatment approaches for endometrial cancers, focusing on proficient mismatch repair (pMMR), deficient mismatch repair (dMMR) diseases and molecular classification in the recurrent setting.

Free

Precision in Endometrial Cancer: Personalized Treatment Strategies for pMMR and dMMR Endometrial Cancer

This interactive 90-minute symposium will explore the evolving treatment landscape in endometrial cancer, focusing on the distinctions between dMMR and pMMR disease.

Free

Surgical Film Library

Curated film collection reviewed by global surgical experts showcasing gynecologic oncology surgery procedures and techniques. Films provide practical learning through surgical demonstrations.

Free

From Data to Practice: Integrating Key Phase III Results into Ovarian Cancer Management

Kathleen Moore details outcome measures from three major phase III trials—KEYNOTE-B96, ROSELLA, and MIRASOL—highlighting objective response rates, progression-free and overall survival, and key safety signals.

Free

Redefining Platinum Sensitivity : Additional Treatment Considerations in a Changing Paradigm

Dr. Robert Coleman with moderation by Dr. Floor Backes and Dr. Wendel Naumman. Dr. Coleman explores the evolving treatment strategies for recurrent platinum-sensitive ovarian cancer, drawing on the latest clinical trial data and real-world outcomes.

Free

IGCS 2024 Endometrial Cancer Master Session

Held at the IGCS 2024 Annual Global Meeting in Dublin, Ireland on October 16, 2024.

Free

2025 IGCS-IGCAN Gynecologic Cancer Survivor-Caregiver Summit

Free

Gestational Trophoblastic Disease ECHO

This monthly ECHO series brings together international experts to advance best practices in the diagnosis, management, and research of gestational trophoblastic disease (GTD) through real-world cases, focused lectures, and interactive discussion.

Free

Patient reported outcomes exploring quality of life in PROC and novel therapeutics: mirvetuximab in recurrent ovarian cancer

Discover how patient-reported outcomes highlight mirvetuximab’s ability to preserve quality of life while delivering meaningful clinical benefits for women with platinum-resistant ovarian cancer.

Free